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Abstract
Background: CR6261 was found in 2008 and F10 was found in 2009. In 2010 Friesen et al experimentally showed that
Oseltamivir/Zanamivir may improve the therapeutic efficacy of CR6261. As a result, the use of CR6261 combined with a drug
to provide an antibody-based therapy against all influenza A viruses was proposed. Although CR8020 may neutralize group
2 influenza viruses and FI6 may neutralize both group 1 and group 2 influenza viruses as determined in 2011, the insight of
Friesen et al is still interesting. Here, we address the following questions: how to uncover the molecular mechanism of a
drug, which improves the therapeutic efficacy of mAbs and how to find drugs that enable CR6261 (CR8020, F10) to become
a universal mAb.
Methods and Findings: Using the 3D structures of 3 gbn, 3 gbm, 3 ztn, 3 ztj, 3 fku and 3 sdy, we separate the 3D structures
of CR6261, F10, CR8020 and FI6, and the 3D structures of trimer HAs of H3N2 and H5N1. Based on the experimental result of
Friesen et al, we have found many clues, which reveal the molecular mechanism of action for a drug and an HA-mAb
complex.
Conclusions: Oseltamivir/Zanamivir may congruously improve the therapeutic efficacies of CR6261, F10, CR8020 and FI6 by
providing an additional affinity to compensate for the loss of affinity between HA and mAb resulting from mutations.
However, Oseltamivir or Zanamivir are not expected to generally widen the spectrum of these mAbs. In order to enhance
CR6261, CR8020, or for F10 to become universal, we may select Azichromycin, Oseltamivir, or the combination of
Azichromycin and Oseltamivir, respectively.
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Introduction
General Background
Since the discovery of the human monoclonal antibody
CR6261 published by Throsby et al ([1], PLoS ONE 2008), the
isolation of an impressively wide spectrum of antibodies and
therefore a family of monoclonal antibodies (mAbs) was made
possible, e.g. F10 ([2], Sui et al, Nat Struct Mol Biol, 2009),
CR8020 ([3] Ekiert et al, Science 2011), FI6 ([4], Corti et al,
Science 2011). It was determined that (a) CR6261 and F10 may
neutralize all group 1 influenza viruses, (b) CR8020 may neutralize
all group 2 influenza viruses, and (c) FI6 is the unique mAb to
neutralize both group 1 and group 2 influenza A viruses. The
discovery of mAbs is the prime mover in the development of new
vaccines and antibody-based therapies. For example, an explora-
tion of improved universal vaccines for all influenza A viruses
based on CR6261-like antibodies was proposed in the papers by
Wei et al ([5], Science 2010) and Nabel et al ([6], Nature 2010).
Also, Friesen et al evaluated the prophylactic and therapeutic
efficacy of the CR6261 antibody against a lethal challenge due to
the highly pathogenic avian H5N1 virus in ferrets ([7], PLoS ONE
2010). They further provided the insight that the use of CR6261 in
combination with an effective drug (i.e., Oseltamivir or Zanamivir)
could become an antibody-based therapy against all influenza A
viruses. These studies have defined a new paradigm in the research
on vaccines and provided a useful starting point for the design of
new vaccines.
Although a universal mAb FI6 has already been found, the
insight for the use of a drug in a complex with CR6261 to
neutralize all influenza A viruses is still worth pursuing, because it
can provide a general method to enhance a wide spectrum of mAb
and enable them to become a universal antibody. This can also
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resistance. Therefore, this approach may lead to multiple choices
for antibody-based therapies. The use of mAb in a combination
with a drug will be easier and cheaper relative to the cocktail
method that is based on two types of mAbs. Therefore, one of the
objectives of this study is to provide a new insight regarding the
utilization of mAbs. With an increasing number of mAbs
becoming available, selectivity of mAbs in combination with drugs
offers an opportunity to construct better mAb-drug combinations.
In this paper, we first determine the molecular mechanism by
which Oseltamivir and Zanamivir improve the therapeutic efficacy
of an mAb. Then, we look for the drugs which enhance CR6261,
F10 or CR8020 to become a universal mAb, respectively. To
perform the latter task, we must first deal with the hard problem of
demonstrating the relationship between mAbs and the trimer HAs
while being fully aware of the fact that mAbs cannot neutralize
influenza viruses. For example, since we know that CR6261
cannot neutralize all group 2 influenza viruses, we should show
that CR6261 and group 2 HAs may be combined first.
The fact that Oseltamivir or Zanamivir in complex with
CR6261 improves the therapeutic efficacy of CR6261 to treat
group 1 influenza viruses is a crucial piece of evidence in support
of the assumption that Oseltamivir must directly act on either
3 gbn or 3 gbm. In fact, we cannot use the cocktail idea to explain
this enhancement of the therapeutic efficacy of CR6261 by adding
Oseltamivir. This is because Oseltamivir is ineffective against
H5N1 when it binds to the NA protein of H5N1 and Oseltamivir
does not bind to the trimer HA alone. Therefore, the complexed
protein (CR6261 with the trimer H5 HA) must be the molecular
target for the action of Oseltamivir. For the same reason, we know
that the CR6261-trimer HA (for all group 1 HAs) must be the
target protein for both Oseltamivir and Zanamivir. In order to
uncover the mechanism by which a drug may improve the
therapeutic efficacy of CR6261, we should look for a clue from the
complex CR6261-trimer HA for all group 1 HAs. The result that
Oseltamivir may improve the therapeutic efficacy of CR6261 in
treatment of H5N1 should also lead to additional clues. For
example, the docking poses between the drug and its benchmark
pockets are known to be very diverse.
Other clues and additional information will be gradually
extracted. For example, based on CR8020, we find that the
footprint of mAb containing an epitope is not a necessary
condition for mAb to neutralize influenza viruses. This clue leads
us to focus on the issue of affinity. However, it is clear that an
antibody is ineffective if its footprint is located on the head of a
trimer HA. To look for underlying clues, one should use both
computational tools and experimental methods. Since this is not
an experimental project, we will use computational modeling to
the greatest extent possible.
Based on all clues deduced from the well-known complexes of
mAbs and HAs, we determine a general molecular mechanism to
explain why a drug may improve the therapeutic efficacy of
CR6261, CR8020, F10 and FI6. In order to look for a drug used
in combination with CR6261, F10 or CR8020 to enable it to
become a universal mAb, or enhance the effect of FI6 to prevent
drug resistance, we need additional insights. They can be used to
show that CR6261 and F10 bind to group 2 HAs and to predict
the location of the footprints of CR6261 (F10) on H3 HA.
Tools and Materials Used
First, we use computational methods, namely protein-protein
docking algorithms to show that CR6261 also bind to group
2 HAs. Clearly, it would be ideal if all spatial structures of group
2 HAs were well known. However, only 3D structures of H3 HA
and H7 HA are available in the Protein Data Bank (PDB). This
small number of structures is obviously insufficient. Fortunately,
the conservation of footprints of antibodies on each of the group
2 HAs ensures that we may be able to infer a general conclusion
based on some representative cases.
The available crystal structures of HAs in a complex with an
antibody are 3 gbn (the H1 HA in complex with CR6261, [8]),
3 gbm (the H5 HA in complex with CR6261, [8]), 3 sdy (the H3
HA in complex with CR8020, [3]), 3 fku (the H5 HA in complex
with F10, [2]), 3 ztj (the H3 HA in complex with FI6, [4]) and
3 ztn (the H1 HA in complex with FI6, [4]). These six crystal
structures form the dataset representing prior knowledge giving us
insights, which will be used to uncover the molecular mechanism
of action. For example, based on 3 gbn and 3 gbm, we find that
the footprints of CR6261 on H1 and H5 are the same. Based on
3 ztn and 3 ztj, we find that the footprints of CR6261 on H1 and
H3 are not the same. Based on 3 fuk and 3 gbm, or 3 sdy and
3 ztj, we find that the footprints of CR6261, F10 and FI6 or
CR8020 and F10 on the same HAs are different. In particular, the
footprint of CR8020 challenges the notion that a footprint must
contain an epitope including a fusion peptide and an aA helix.
The conservation of a footprint helps us find the common
conserved area on the surface of a stem of group 1 HAs or group
2 HAs. This conserved area is larger than the union of the
footprints from a wide spectrum of mAbs on group 1 HAs or
group 2 HAs. For this purpose, we need to use multiple sequence
alignment algorithms and the benchmark dataset of all available
HA sequences. Since public algorithms [9–17] do not work well
for large-size datasets, we have decided to use a new multiple
sequence alignment algorithm MCABMSA (introduced in Section
4 of Information S1). Using MCABMSA, we have generated a
dendrogram of H1–H16 and the consensus sequences of H1–H16.
According to the five-group method used in ref. [2], we carry out a
conservation analysis of residues in a site-by-site fashion. As a
result, we have been able to construct the conserved area on the
surface of group 1 HAs and group 2 HAs, respectively.
In order to look for the binding pocket of Oseltamivir/
Zanamivir on the target protein 3 gbn, we use AutoDock [18–22].
It is a good tool for finding the binding pocket of a drug on a given
target protein. We have no reason to doubt the quality of
AutoDock. However, having performed large-scale validation
exercises, we noticed that AutoDock has a tendency to be trapped
in local energy minima. As a consequence, it appears that
AutoDock often sends ligands to the same area where all input
drugs arrive at their minimum free energy locations. Our large-
scale validation is shown in Section 1 of Information S1. This
specific property encourages us to utilize this software to search for
a binding pocket using a panel of drugs. For different cases studied,
we have assembled different panels of drugs. In general, the panel
of drugs used should have a balanced distribution with an
appropriate rate between positive and negative controls. In this
paper, the panel of nine drugs used consists of Amantadine,
Azithromycin, Aspirin, HEM, Heroin, Isosorbide, Oseltamivir,
Zanamivir, and Vancomycin. Details regarding the choice of the
panel of drugs are given in Section 2 of Information S1. How to
explore the binding pocket on a given target protein based on a
panel of drugs is stated in Section 1 of Information S1.
Although CR6261 was validated experimentally to neutralize
group 1 influenza A viruses, its molecular mechanism of action has
not been uncovered yet. To determine the mechanism, we analyze
all 3D structures of the HA-CR6261 complex for all group 1 HAs.
This is because we can use it to obtain a critical affinity for
CR6261 neutralizing group 1 influenza viruses. Nevertheless, we
have only used 3 gbn with 3 gbm, which are partial crystal
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respectively. As additional support, we have used all crystal
structures 3 gbn, 3 gbm, 3 fuk, 3 sdy, 3 ztn and 3 ztj as a test
panel to estimate the critical affinity for an mAb neutralizing the
influenza viruses. Then, we have used the Ligand Explorer
software and the molecular dynamic simulation (MD) software
(e.g., GROMACS) to estimate the upper bound of the binding free
energy for an antibody to unbind from an HA. As an introduction
to MD simulations, we refer the reader to ref. [23].
As approximate models of the crystal structure of CR6261 or
F10 in complex with H3 HA, we use the predicted 3D structures.
For this purpose, we need to use the protein-protein docking
software (RosettaDock). As an introduction to the topic of protein-
protein docking, we recommend refs. [24–26].
Before we discuss the results obtained, we need to explain the
benchmark dataset in more detail. We first downloaded all
sequences of influenza A viruses from the Uniprot database
updated on Dec.6, 2010. We then retrieved all HA sequences. All
A-type sequences were classified into 16 types, denoted by H1, H2,
etc., up to H16. To avoid confusion, we simply denoted C-type
HA sequences and B-type sequences as HC and HB, respectively.
The total number of HA sequences in the benchmark dataset is
36,051 (some sequences of a mixed or unidentified type have not
been deleted from this dataset) and we have used these 36,051
sequences as the benchmark dataset in this paper. Section 3 of
Information S1 shows how to obtain this dataset in detail.
Since we have used the unpublished multiple sequence
alignment software MCABMSA, it is worth explaining the reason
for it. Numerous software packages are readily available for use,
for example, BLAT [9], AVID [10], MUSCLE [11], COFFEE
[12], SAGA [13], MAVID [14], MSAID [15], Mauve [16] and
MAFFT [17]. However, the first 8 algorithms are slow and do not
work well for datasets with 5,000 sequences or more. Comparably,
MAFFT is very fast, but it also does not work well for datasets with
10,000 sequences or more. In the benchmark dataset, the number
of sequences of H1 or H3 is equal or larger than 10,000.
Therefore, we have decided to use the novel multiple sequence
alignment software MCABMSA, whose full name is ‘‘Multiple
Compressed and Anchor-Based Multiple Sequence Alignment for
the Sequences of Viruses’’. It involves four parameters: (1) the
length of an anchor point, (2) the number of wrong letters that are
tolerated, (3) the maximum relaxed number, and (4) the coverage
rate of anchor points. A brief description of the function of each
parameter and the advantage of MCABMSA is provided in
Section 4 of Information S1.
Materials and Methods
Retrieving Side Information
It will be very convenient to directly use the dendrogram of H1–
H16 used in refs. [2–6], which was constructed based on 39
representative sequences. Moreover, if we use these 39 represen-
tatives to analyze the conservation of residues of HAs in the five-
group fashion [2], this will save us a large amount of space. We
need to look for useful clues when reconstructing the dendrogram
of H1–H16 and when reanalyzing the conservation of residues
based on the sequences made available over the past 90 years. The
numbers of all subtypes are listed in Table 1.
Retrieving Side Information by Reconstructing the
Dendrogram
A convenient method to reconstruct the dendrogram of H1–
H16 is to group all available sequences into a few clusters using
MCABMSA under each given parameter r. We then transform
each cluster as an 18-dimensional vector using the following steps:
1. Compute rk = the number of the k-th type of HA sequences appearing in
the cluster as a function of the number of the k-th type of HA sequences
shown in Table 1.
2. Transform the cluster into the vector v=( r 1,r2,r3,r4,…,r18).
Analyzing the components of each vector, we readily recognize
which Hk sequences are grouped into the same cluster. For
example, MCABMSA may output 7 clusters after being aligned
under r=0.001. Among the corresponding 7 vectors, only 5
vectors have the maximum components that are greater than 0.01
as listed in Table 2.
In Table 2, HA_k denotes a vector corresponding to the cluster
HA_k. For a given vector, each of the 18 components is the rate of
the number of these sequences grouped into the cluster HA_k as a
function of the total number of sequences as shown in Table 1.
From Table 1, we find that most of H4, H5 and H14 sequences
and a part of H3 sequences which share a common peptide with
HC sequences. The second vector tells us that most of the H1, H2,
H6, H7, H8, H9, H10, H12, H13, H15, H16 and HB sequences
share a common peptide with HB sequences. The first and the
second vectors jointly show that the HB and HC sequences have
no common peptide. The third vector shows that a large number
of H3 sequences have no peptide in common with both HC and
HB sequences. These vectors not only give us an approximate
relationship among these 18 classes of sequences, but also
determine the common peptides, if we inversely track them from
the cluster. For example, the common peptide shared by H1, H2,
H6, H7, H8, H9, H10, H12, H13, H15, H16 and HB sequences is
the palindrome peptide FGAIAGF.
To distance H1–H16 from HB and HC, we need to gradually
enlarge the parameter r.A sr . 0.2, we find that the HB and HC
sequences are significantly separated from the H1–H16 sequences.
Therefore, for consistency we select 0.4, 0.5, 0.6, 0.7 and 0.8.
Then we have 6 groups of vectors formed. According to these 6
groups of vectors, we plot 6 figures. These 6 figures exactly show
that progression of the dendrogram of H1–H16 as r increases
equidistantly. At r=0.8 this dendrogram virtually coincides with
that dendrogram used in refs. [2–6]. In other words, we have
successfully reconstructed the dendrogram in a new way. For more
details, the reader is referred to Section 5 of Information S1. The
value of this exercise is to help identify which peptides play the role
of important markers among the H1–H16 sequences. These
peptides will be used as side information in order to find the
molecular mechanism of action.
Retrieving side information by reanalyzing the
conservation of residues. The main idea to reanalyze the
conservation of the residues on the surface of HA using the five-
group method based on all available sequences is stated as below:
1. Rebuild datasets of HA1 and HA2 based on the benchmark
dataset. The key to doing this is to use the palindrome peptide
FGAIAGF as the maker to divide all H1–16 sequences into
HA1 and HA2. Coincidentally, peptide FGAIAGF has already
been used earlier as a marker to divide HA1 and HA2 ([27],
Skehel and Waterfield 1971).
2. Rebuild HA1A and HA1B based on the datasets of HA1. The
key to doing this is to use the highly conserved peptide
WGIHHP as the marker found by MCABMSA with r=0.001
to align the dataset of HA1.
3. Rebuild HA2A and HA2B based on the datasets of HA2. The
key to doing this is to use the highly conserved peptide
Molecular Mechanism through Computational Analysis
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0.001 to align the dataset of HA2.
4. HA1B is a longer segment and all amino acids on the head of a
spike are contained in the first region of this segment. Using the
peptide C***C****G which is located at the head of a spike but
links the stem of the spike as a marker, we can further divide
HA1B into HA1B1 and HA1B2.
5. HA1A, HA1B2, HA2A and HA2B are four segments
containing the regions 1–58 and 302–344 on HA1 and the
regions 3–87 and 94–196 on HA2, respectively.
These four regions form the stem of HA. For more details
regarding how to divide the stem and head the reader is referred to
Section 6 of Information S1. The details on how to get datasets of
HA1A, HA1B2, HA2A and HA2B are shown in Section 7 of
InformationS1.BasedonthedatasetsofHA1A,HA1B2,HA2Aand
HA2B,wecanreanalyzetheconservationofpeptidesinfourregions
site-by-site in five-group fashion. The final result is shown in Tables
S13 and S14 separately in Section 8 of Information S1. Comparing
Table S12 with Tables S13 and S14, we find that our conservation
analysis is just an extension of Table S12 used in ref. [2].
Using 1rd8 and 1 mql as the models of group 1 HAs and group
2 HAs, we read off the common conserved area on group 1 HAs
and group 2 Has, respectively based on Tables S13 and S14.
Furthermore, we find the footprint of CR6261 on H1 HA, the
footprint of F10 on H5 HA and the footprint of FI6 on 1rd8,
respectively. For clarity, we highlight the conserved area with
yellow, the footprint of CR6261 with red, the footprint of F10 with
blue, and the footprint of FI6 with green. In the same way, the
footprint of CR8020 on H3 and the footprint of FI6 on H3 are
found on 1 mql, respectively. Shown in yellow is a conserved area,
the red area means the footprint of CR8020 and the green area
means the footprint of FI6. This is shown in Figure 1 (A) and (B).
Figure 1 (A) shows that the conserved area on group1 almost
contains the footprints of CR6261, F10 and FI6, and all footprints
contain the epitope (fusion peptide and the aAhelix). Figure 1 (B)
shows that the conserved area on group 2 almost contains the
footprints of CR8020 and FI6. Notably, the footprint of CR8020
does not contain the epitope, which means that it is important to
review the role of mAb. That is, the location of the footprint is not
the key, but how to prevent HA from being separated is the key.
Therefore, how to improve the affinity between mAb and HA and
how to prevent the structure of a trimer HA from being broken is
crucial.
In Figure 1 (A) and (B) we also find a green line over the union
of all footprints, which corresponds to the peptide
C***C****G*****PFQN. Moreover, the highly conserved peptides
GECPKYV and LRLATGLRNVP are also outside of the union
of all footprints. This also provides important side information.
The asterisk * means that the amino acid of H1 HA and the amino
acid of H3 HA in this position are different but it is almost
invariant within H1 or H3 taken individually. Specifically,
C***C****G (277–286) is located in the head of HA, while PFQN
(sometimes PFHN) is located at the stem of HA.
Determining the Molecular Mechanism of Action
The exploration of the binding pocket using a panel of
drugs. Since Oseltamivir and Zanamivir may enhance the
therapeutic efficacy of CR6261 to treat group 1 influenza viruses,
we infer that 3 gbn and 3 gbm must be the target proteins for
Oseltamivir and Zanamivir. To explore where on 3 gbn or 3 gbm
the binding pocket of Oseltamivir and Zanamivir is located, we use
AutoDock to search for the pocket using computational methods
because we have no experimental means to do so. How to use it
with a panel of drugs and a panel of target proteins to enhance the
reliability of AutoDock has been mentioned in Section 1.2 of the
Introduction. Typically, we explore the location of the binding
pocket as follows.
1. Based on the panel of drugs and the panel of target proteins, we
use AutoDock to blindly dock, one by one, the 9 drugs with the
6 target proteins.
2. Within the output of the drug and protein pair, we choose the
pose ranked number 1 in the first cluster to be the optimal pose
for each drug and protein pair.
3. On each target protein, we use PyMOL to show all of these
optimal poses with negative values of MFE at the same time.
4. The cave/groove is called a binding pocket if it contains the
union of these optimal poses with a negative value of MFE.
Using the above method of exploration, we obtain six pockets
shown in Figure 2 (A)–(F) which represents the cleft formed by
mAbs and HAs. We denote them as pocket_3 gbn, pocket_3 gbm,
pocket_3 fku, pocket_3 sdy, pocket_3 ztj and pocket_3 ztn, re-
Table 1. The numbers of HA sequences for 18 cases in the benchmark dataset.
HC HB H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 H13 H14 H15 H16
54 3002 9837 315 14235 467 4301 739 989 56 1354 201 145 63 69 7 10 24
doi:10.1371/journal.pone.0037790.t001
Table 2. The vectors induced from the five clusters.
C B H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 H13 H14 H15 H16
HA_1 1.0000 0.0000 0.0003 0.0000 0.2952 0.8843 0.7901 0.0000 0.0010 0.0000 0.0185 0.0000 0.0000 0.0000 0.0000 0.8571 0.0000 0.0000
HA_2 0.0000 1.0000 0.7975 0.7922 0.1590 0.0306 0.1301 0.9318 0.9342 0.9800 0.8175 0.9353 0.9379 0.9661 0.9848 0.1429 0.9000 0.9583
HA_3 0.0000 0.0000 0.1619 0.0519 0.5203 0.0699 0.0780 0.0655 0.0648 0.0000 0.0542 0.0647 0.0207 0.0339 0.0000 0.0000 0.1000 0.0417
HA_5 0.0000 0.0000 0.0404 0.1558 0.0000 0.0087 0.0019 0.0027 0.0000 0.0200 0.0853 0.0000 0.0414 0.0000 0.0152 0.0000 0.0000 0.0000
HA_6 0.0000 0.0000 0.0000 0.0000 0.0256 0.0066 0.0000 0.0000 0.0000 0.0000 0.0245 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
doi:10.1371/journal.pone.0037790.t002
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HA and CR6261, H5 HA and CR6261 (i.e., 3 gbn and 3 gbm)
are different even though the footprints are the same. Figure 2 (E)–
(F) (i.e., 3 ztn and 3 ztj), shows that both the angles and footprints
of FI6 on group 1 and group 2 HAs are different.
Let the pose of the drug bound to the pocket with the globally
minimum free energy be the optimal pose. Then slight differences
between the angles will result in variations of the optimal pose.
Intuitively, Figure 1 (A) shows that the optimal pose of Oseltamivir
docked to pocket_3 gbn can improve the affinity between H1 HA
Figure 1. Comparison between the conserved area and the footprints. (A) The conserved area (green), the footprint of CR8020 (red), and the
footprint of FI6 (purple) on group2 HA. The overlap between footprint of CR8020 and footprint of FI6 is yellow. (B) The conserved area (green), the
footprint of CR6261 is Cambridge blue and yellow, the footprint of F10 is navy blue and yellow, and the footprint of FI6 is completely covered by
yellow on group 1 HA.
doi:10.1371/journal.pone.0037790.g001
Figure 2. The pocket on 3 gbn, 3 gbm, 3 fku, 3 sdy, 3 ztn and 3 ztj explored using AutoDock based on one subunit. (A) The pocket of
drugs on 3 gbn is the fork. (B) The pocket of drugs on 3 gbm is the fork. (C) The pocket of drugs on 3 fku is the fork. (D) The pocket of drugs on 3 sdy
is the fork. (E) The pocket of drugs on 3 tzn is the fork. (F) The pocket of drugs on 3 tzj is the fork.
doi:10.1371/journal.pone.0037790.g002
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while Figure 1 (B) shows that the optimal pose of Oseltamivir
docked to pocket_3 gbm will not do so because Oseltamivir only
binds to CR6261.
In order to quantitatively analyze the additional affinity
provided by a drug in the optimal pose, we use Ligand Explorer
to compute all hydrogen bonds and all hydrophobic interactions
for each optimal pose. For simplicity, we do not distinguish
hydrogen bonds and hydrophobic interactions and both are called
by a joint name, non-covalent bonds. Then all non-covalent bonds
can be classified into two sets. The non-covalent bonds between
the ligand and HA are classified into the left set and the non-
covalent bonds between the ligand and mAb are classified into the
right set. We denote the numbers of left and right sets by a, b
respectively. It is clear that a+b is proportional to the total binding
affinity of a drug docked to the given pocket in the optimal pose. It
is logical to expect that min{a, b} rather than a+b is the key
parameter for improving the affinity between HA and mAb.
Therefore, we infer that the therapeutic efficacy of CR6261 will be
improved by a drug if min{a, b}.0.
Specifically, for the 9 optimal poses produced by the 9 drugs
docked to pocket_3 gbn, we find the values a, b, a+b and min{a,
b} for the 9 optimal poses on pocket_3 gbn, which are shown in
Table 3. This shows that Oseltamivir and Zanamivir hold promise
to enhance the therapeutic efficacy of CR6261 for H1 influenza A
viruses because min{a, b}=4. Aspirin and Heroin appear to be
ineffective since min{a, b}=0. Isosorbide and Amantadine also
seem ineffective because min{a, b}=1 is too small. Azithromycin
is the best candidate among these 9 drugs since min{a,b}=13 is
the largest value found. This indicates that we may have found a
molecular mechanism which explains why Oseltamivir/Zanamivir
improves the therapeutic efficacy of CR6261 on H1 influenza
viruses.
We further compute the values a, b, a+b and min{a, b} of the 9
optimal poses for pocket_3 gbm, pocket_3 ztn, pocket_3 ztj,
pocket_3 fku and pocket_3 sdy, respectively. The results are
shown in Table S16 of Section 9 of Information S1. Contrary to
our expectation, we find that min{a, b}=0 in pocket_3 sdy for all
9 drugs, and min{a, b}=0 for Oseltamivir and Zanamivir in
pocket_3 gbm. The latter result can be interpreted as an inability
of Oseltamivir and Zanamivir to improve the therapeutic efficacy
of CR6261 for H5 if this binding site is unique in this pocket.
However, this is contrary to the results obtained in the experiment
of Friesen et al. This contradiction causes us to rethink the other
poses of Oseltamivir within the pocket_3 gbm.
For the simplicity of computation, we will not distinguish
between the pose and the coordinates. This is because each pose is
determined by recalculated coordinates of the drug obtained
through shifting or rotating its original 3D coordinates. Converse-
ly, renewed 3D coordinates of the drug also uniquely determine a
pose.
The neighborhood of a pose. A minor flaw of AutoDock
which has been mentioned in Section 1 of Information S1 is that
the optimal pose of Indinavir is not same as its real pose on the
HIV-1 protease. Huey et al in 2007 [11] ascertained that the root-
mean-square deviation (RMSD) between the real pose and the
optimal pose is approximately 2.5 angstroms. For a given pose, we
define the set of these poses within the pocket, which are within a
2.5A distance of the given pose, as the neighborhood of the pose.
Clearly, the number of the poses in the neighborhood of a given
pose is infinite. Therefore, this will also lead to a huge number of
associated poses if we move the optimal pose to a real pose within
the neighborhood of the optimal pose by applying operation of
shifting and rotating. In other words, in practice we cannot
compute all distributions of the non-covalent bonds for all
associated poses. It is fortunate that distributions of non-covalent
bonds are invariant if two associated poses are close enough.
Therefore, due to the compactness of the neighborhood of a pose
we may need to check a finite number of associated poses rather
than to check all possible associated poses within the neighbor-
hood.
It is not hard to imagine that a drug docked to a benchmark
pocket will exhibit multiplicity of conformers (multiformity)
because there is no means to ensure it must exactly bind to its
benchmark pocket according to the designed pose. In fact, based
on the available experimental results measured by x-ray crystal-
lography, we can explore this multiformity of experimentally
determined poses. For example, ADP is a well-known ligand
which binds to many hundreds of proteins and has many
benchmark pockets on each target protein. For example, the first
group contains 12 proteins which are 1688_A, 1 yrs_A, 2 fky_B,
2fl2_A, 2fl6_A, 2g1q_B, 2q2y_A, 2q2z_B, 2 wog_A, 267d_A,
267e_B and 3 cjo_A. The second group contains 11 proteins
which are 1 bmf_D, 1e1q_D, 1e1r_D, 1efr_D, 2ck3_D, 2jiz_D,
2jj1_D, 2jj2_K, 2v7q_F, 2w6e_D and 2 wss_M. All of these
proteins may be bonded by ADP. We assume that 12 poses are the
poses of ADP docked to the same protein 1688_A by
independently repeating it 12 times and that 11 poses are the
poses of ADP docked to the same protein 1 bmf_D by repeating it
independently 11 times. Gathering the 12 poses on 1688_A and
the 11 poses on 1 bmf_D, we find that in practice ADP docks to
the same benchmark pocket on 1688_A or 1 bmf_D with multiple
poses. A detailed validation is stated in Section 10 of Information
S1.
Generally, it is believed that the molecules of a drug randomly
collide with the benchmark pocket with no control over the exact
docking mode to the benchmark pocket. Therefore, the real
binding poses span a manifold within a neighborhood of a given
pose. A drug is effective if most of the actual poses play the same
effective role in binding to the target. Conversely, a pose is
ineffective if all poses in the neighborhood of the pose play the
same ineffective role.
Table 3. The distribution of non-covalent bonds of the drug
on 3 gbn.
ligand a+b a b Min{a,b}
Azithromcyin 36 23 13 13
Oseltamivir 17 13 4 4
Zanamivir 17 13 4 4
HEM 27 9 18 9
Aspirin 24 24 0 0
Isosorbide 21 20 1 1
Vancomycin 19 16 3 3
Amantadine 9 8 1 1
Heroin 18 18 0 0
Here, a is the number of non-covalent bonds between a drug and HA; b is the
number of non-covalent bonds between a drug and CR6261; a+b is the total
number of non-covalent bonds between a drug and the complex HA and
CR6261; and min{a, b} is the minimum number between a and b. This table
shows that Azithromcyin is best overall; Oseltamivir and Zanamivir also enhance
the prophylactic and therapeutic efficacy of the CR626 antibody. Aspirin and
Heroin appear to be ineffective. Both Isosorbide and Amantadine are almost
ineffective.
doi:10.1371/journal.pone.0037790.t003
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poses in the neighbor of the given pose playing the same role as the
given pose versus the total number of poses in the neighbor as the
tolerance of the pose. Following from the definition of tolerance,
we easily find that a drug has high efficacy if the designed pose of
the drug binding to its benchmark pocket has high tolerance. As
mentioned before, the number of associated poses within the
neighborhood of a given pose is huge. Therefore, the computation
of the tolerance of a pose in practice should be approximated by a
simplified method. For n associated poses, if m associated poses
play the same role as the given pose, then we use the ratio m/n as
the estimation of the tolerance of the given pose.
Specifically, for the optimal pose of Oseltamivir or Zanamivir
binding to the pocket_3 gbm, we have randomly selected many
associated poses in the neighborhood of the optimal pose and
computed the numbers a and b and we find that min{a, b}=0 for
all of these selected associated poses. Therefore, the optimal pose
of Oseltamivir or Zanamivir binding to the pocket_3 gbm is
ineffective. This unexpected result further leads us to look for the
real cause that Oseltamivir or Zanamivir improves the therapeutic
efficacy of CR6261 to treat H5 influenza viruses.
The size of the benchmark pocket. Analyzing the size of
pocket_3 gbm, we find it is large enough to be filled with more
than two molecules of Oseltamivir. Therefore, we classify pockets
into two classes according to a given drug. For a given drug, we say
the pocket is small relative to the drug if the pocket cannot be filled
with two or more molecules of the drug. Otherwise, we say that it
is a large pocket relative to the drug. In other words, a small pocket
may only have one neighborhood of the optimal pose, while a
large pocket may contain at least two neighborhoods of two poses
without an overlap. For small pockets, we frequently do not find
an associated pose in the neighborhood of the optimal pose such
that min{a1, b1}. min{a, b} through shifting and rotating the
optimal pose. However, for a large pocket, we frequently find an
associated pose so that min{a1, b1} . min{a*, b*} and that the
neighborhoods of these two poses do not overlap. Here, min{a1,
b1} is the contribution of the associated pose and min{a*, b*} is
the contribution of the optimal pose.
Specifically, the existence of an associated pose in a large pocket
such that min{a1, b1}. min{a, b} for all 6 pockets and 9 drugs is
shown in Table S17 of Section 9 of Information S1. In Table S17,
for all 54 optimal poses we find 54 associated poses such that
min{a1, b1} . min{a*, b*}. From the data in Table S17, we find
that Oseltamivir and Zanamivir at an associated pose which is far
from the optimal pose can substantially improve the affinities
between CR6261 and group 1 HAs, between F10 and group
1 HAs, between CR8020 and group 2 HAs, and between FI6 and
HA for all subtypes.
It appears that the essential cause that Oseltamivir and
Zanamivir may improve the therapeutic efficacy of CR6261 to
treat group 1 influenza viruses has finally been found. However,
there is still a gap that should be closed. That is, we need to answer
whether the drug’s molecule may arrive in the neighborhood of
the associated pose? We answer the question by stating the
following property:
If a drug molecule in a large pocket has two poses such that their
neighborhoods do not overlap, then the neighboring pose may be
adopted by the drug molecule.
The proof of this property is not hard to arrive at. In fact, we
regard a pocket just as the union of the two neighborhoods. Then
this pocket is regarded as a bag with two boxes and each box can
be packed into one ball. Since more than two molecules of the
drug may enter into the pocket, it implies that more than two balls
may enter into the bag. Therefore, it is certain that each box binds
one ball.
The molecular mechanism to enhance the therapeutic
efficacy of mAb. Based on the above computational analysis,
we summarize the clues found and propose the molecular
mechanism of action as follows:
1) For CR6261 (F10) which may neutralize group 1 influenza
viruses and their footprints which contain the epitope, a drug
may enhance the therapeutic efficacy of CR6261 (F10) if and
only if it has a high tolerance pose satisfying min{a, b}.0 for
group 1 HAs.
2) For CR8020 which may neutralize group 2 influenza viruses
but its footprint is located on HA2 although it does not
contain the epitope, a drug may enhance the therapeutic
efficacy of CR8020 if and only if it has a high tolerance pose
satisfying min{a, b}.0 for group 2 HAs.
3) For F16 which may neutralize both group 1 and group 2
influenza viruses and their footprints contain the epitope, a
drug may enhance the therapeutic efficacy of FI6 if and only
if it has a high tolerance pose satisfying min{a, b}.0 for all
HAs.
Following from the above mechanisms and using the data in
Table S17, we deduce that both Oseltamivir and Zanamivir may
enhance the therapeutic efficacy of CR6261, CR8020, F10 and
FI6 within their original spectrum. The other drugs do not lead to
stable associations with Oseltamivir and Zanamivir having a high
tolerance pose.
The Drug Resistance of Antibody-drug Complexes
To identify an antibody-drug complex without drug resistance,
we should estimate the affinity between HA and mAb. We should
also determine how much affinity would be lost if the HA is
changed and how much additional affinity would be provided by
the drug. Moreover, it is useful to know whether or not the added
affinity depends on the specific HA. We answer these questions
one by one in the subsection that follows.
Estimation of the range of affinity between an antibody
and HA. The affinity between an mAb and an HA is
determined by multiple factors (i.e., hydrogen bonds, hydrophobic
interactions, van de Waals forces, etc.), therefore we can hardly
compute its value precisely. In practice, we use GROMACS to
directly estimate the affinity between antibodies and HAs based on
3 gbn, 3 gbm, 3 fku, 3 sdy, 3 ztn and 3 ztj. Typically, we may use
a large constant force (2,500 kJ/mol nm) to pull the CR6261,
CR8020, F10 and FI6 far away from an HA along a fixed
direction. We plot the distance-versus-time function and look for
the time interval corresponding to a distance of 1A. We then trace
it back to find the output energies corresponding to the given time
interval. We use the energy corresponding to the left terminal of
the interval and the energy corresponding to the right terminal of
the interval as the lower and upper estimates of the affinity
between HAs and mAbs, respectively. Typically, we estimate the
range of affinities between HAs and mAbs as shown in Table 4.
From Table 4, we find that affinity depends on the subtype. This
clue is vital, but we need to confirm it further.
The maximal losing of affinity between mAb and HA as
the HA changed. To estimate the maximum loss of affinity
between CR6261 (F10, FI6) and HA as HA ranges for group 1 or
the maximum loss of affinity between CR8020 (FI6) and HA as
HA ranges for group 2, we alternatively estimate the maximum
loss of the non-covalent bonds between CR6261 (F10, FI6) and
HA in group 1 or between CR8020 (FI6) and HA in group 2.
Molecular Mechanism through Computational Analysis
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37790Therefore, we should know which amino acids in the footprint of
CR6261 (F10, CR8020, FI6) are the potential contributors
towards non-covalent bonds. Since the lengths of the hydrogen
bonds or hydrophobic interactions are less than 4 angstroms, we
readily find the potential contributors within the footprint for each
case. This is shown in Table 5.
Obviously, there is no strict obligation to contribute non-
covalent bonds. We use Ligand Explorer to filter these potential
contributors which give no actual contribution from the set if we
regard it as a ligand. Based on the conservation analysis mentioned
in Section 2.2, we know that the loss of non-covalent bonds is due
to the mutations of these real contributors which come from HA1
(A-chain) because the contributors which come from HA2 (B-
chain) are invariant. That is, we only care about the mutations of
these contributors on HA1.
In particular, we select all actual contributors for 3 gbn, 3 gbm,
3 fku, 3 sdy, 3 ztj and 3 ztn, and obtain the sum of non-covalent
bonds contributed by these contributors, and further infer the
maximum loss of non-covalent bonds as follows:
1. The total number of non-covalent bonds between CR6261 and
H1 is 36. 11 of 36 are contributed by 291S, 38H, 40V and 42L
on HA1. Then, 3 of these 11 are contributed by the atoms on
the backbone or by the first level of residues, and therefore the
maximum loss is 8 if H1 HA is replaced by other group 1 HAs.
2. The total number of non-covalent bonds between CR6261 and
H5 is also 36. But 7 of the 36 are contributed by 293P, 291S,
38H and 42L on HA1. Then 1 of these 7 is contributed by the
backbone and therefore the maximum loss number is 6, if H5
HA is replaced by other group 1 HAs.
3. The total number of non-covalent bonds between F10 and H5
is 23, and only 2 non-covalent bonds are contributed by the
amino acids 292S and 32H on HA1. Then, the maximum loss
number is 1 if H5 is replaced by other group 1 HAs.
4. The total number of non-covalent bonds between CR8020 and
H3 is 34. Only 1 non-covalent bond is contributed by the
amino acid 325E on HA1. Then, the maximum loss number is
at most 1 if H3 HA is replaced by other group 2 HAs.
5. The total number of non-covalent bonds between FI6 and H1
is 44, 12 of the 44 are contributed by 289S, 28H and 316T on
HA1. Then, the maximum loss number of the non-covalent
bonds is 7 if we assume that all group 1 HAs are mutated from
H1. This is because 5 are contributed by the backbone or the
first and second level of the side chains of amino acids.
6. The total number of non-covalent bonds between FI6 and H3
is 26; 1 of these 26 is contributed by 318T on HA1. We find
that maximum loss number of the non-covalent bonds is at
most 1 if H3 HA is replaced by other group 2 HAs.
Using the above observations, the real contributors and all
potential contributors listed in Table 5, the footprints of CR6261,
F10 and F10 all involve the peptide sequence
C***C****G*****PFQN. The maximum loss is overestimated. In
practice, the real loss is often much less than that.
The left and right footprints of Oseltamivir for the pose
with high tolerance. Inspecting Table S17 again, we find that
Oseltamivir may supplement more than 10 non-covalent bonds to
improve the affinities of 3 gbn, 3 gbm, 3 fku, 3 sdy, 3 ztn and
3 ztj. We wish to known if the contributions of Oseltamivir are
affected by mutations. We list the contributors in the left and right
footprints of Oseltamivir based on the 6 crystal structures.
Following these sites in different proteins, we can easily find
where they are located. From Table 6, we find that
C***C****G*****PFQN is the source of the left contributors of
Oseltamivir docked with the forks of 3 gbn, 3 gbm, 3 fku, 3 ztn
and 3 ztj.
For the H1-H2-H5 and H8-H9-H12 subgroups,
C***C****G*****PFQN is conserved and the common form is
CDAKCQTPQGAINSSLPFQN.However,itisslightlymutatedin
H6, H11, H13 and H16. For most HAs in group 2,
C***C****G*****PFQN becomes CNSECITPNGS-
SIPNDKPFQN. It is slightly changed in H4, H14, H7, H10 and
Table 4. Estimates of the affinity between an antibody and
HAs at 1A (in units of kJ/mol).
H1 H5 H3
CR6261 665–719 618–633 *98–111
CR8020 *126–136 – 490–534
F10 – 654–688 *170–180
FI6 838–922 – 481–502
Here, the boldfaced data are estimated based on the real crystal structures, and
the data marked with a star are estimated based on the predicted structures.
The symbol ‘‘-’’ means that structures corresponding to the trimer HA and mAb
are absent.
doi:10.1371/journal.pone.0037790.t004
Table 5. All potential contributors within a footprint for each mAb on three HAs.
mAb HAs Potential contributed amino acids
CR6261 H1 A_38_H A_40_V A_41_N A_42_L A_291_S A_292_L; B_19_D B_20_G B_21_W B_38_Q B_41_T B_42_Q B_45_I B_46_D B_49_T B_52_V
B_53_N B_56_I
CR6261 H5 A_38_H A_40_Q A_41_D A_42_I A_291_S A_292_M A_293_P A_318_T; B_19_D B_20_G B_21_W B_38_C B_41_T B_42_Q B_45_I B_46_D
B_49_T B_52_V B_53_N
F10 H5 A_32_H A_34_Q A_292_S; B_18_V B_19_D B_20_G B_21_W B_38_K B_41_T B_42_Q B_45_I B_49_T B_52_V B_53_N
CR8020 H3 A_21_P A_325_E; B_15_E B_16_G B_17_M B_18_I B_19_D B_25_R B_26_H B_30_E B_31_G B_32_T B_33_G B_34_Q B_35_A B_36_A
B_38_L B_146_N B_150_E B_153_R
FI6 H1 A_28_H A_29_S A_289_S A_316_T; B_18_V B_19_D B_20_G B_21_W B_38_L B_39_K B_41_T B_42_Q B_43_N B_45_I B_46_D B_49_T
B_53_N B_56_I B_57_E
FI6 H3 A_38_N A_277_C A_278_I A_318_T; B_18_I B_19_D B_20_G B_21_W B_38_L B_39_K B_41_T B_42_Q B_43_A B_45_I B_46_D B_48_I
B_49_N B_53_N B_56_I B_57_E
doi:10.1371/journal.pone.0037790.t005
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four mAbs.
In conclusion, the results of Sections 2.2 and 2.3 tell us that
Oseltamivir may enhance the therapeutic efficacy of CR6261, F10
and FI6 to treat group 1 influenza viruses without resulting in drug
resistance, and it can also enhance the therapeutic efficacy of
CR8020 and FI6 to treat group 2 influenza viruses without causing
drug resistance.
The Molecular Mechanism to Promote a Wide Spectrum
mAb to Become Universal
Confirming that CR6261 and F10 may connect to H3 HA
and CR8020 may connect to H1 HA. In order to prove that a
drug may enhance CR6261 and F10 to become universal mAbs,
we must first confirm that CR6261 and F10 may bind to group
2 HAs. Similarly, in order to prove that a drug may enhance
CR8020 to make it a universal mAb, we must first confirm that
CR8020 may bind to group 1 HAs. However, this is hard to do in
the absence of crystal structures for these possible mAb-HA
complexes. As the best recourse, we use RosettaDock to simulate
how CR6261 and F10 bind to H3 HA and how CR8020 binds to
H1 HA.
Of course, the precondition is whether we can use RosettaDock
correctly. Therefore, we use 3 gbn, 3 gbm, 3 fku, 3 sty, 3 ztn and
3 ztj as samples to validate that RosettaDock has the ability to
obtain similar results to those of the 6 crystal structures.
Unfortunately, the results computed by RosettaDock are quite
different from the known 3 gbn structure, if we first separate
CR6261 and A-chain+B-chain from 3 gbn, and then input
CR6261 and A-chain+B-chain into RosettaDock. In the same
way, we find the computed results of RosettaDock for 3g bm,
3 fku, 3 sty, 3 ztn and 3 ztj are also quite different from their
crystal structures.
Accidentally, we have found that 3 ztj has complete trimer HA
data and we input the trimer HA and FI6 into RosettaDock. Then
we use the docking pose with the minimum free energy within
1,000 iterations as the computed docking pose between the trimer
HA and FI6. We find that the computed pose is very similar to the
original crystal structure (see Figure 3(A)).
Encouraged by this finding, we continue our search for the
trimer HA-mAb complex. Nevertheless, only for 3 fku (the H5 HA
in complex with F10) can we find a complete trimer HA-mAb
complex. In the same way we used to process 3 ztj, we obtain the
computed pose of F10 docked with trimer HA and we compare it
with the original crystal structure of 3 fku shown in Figure 3B. In
other words, using mAb to dock to the trimer HA, RosettaDock
has obtained a reliable pose.
In order to find a trimer HA based on 3 gbn and 3 gbm, we
have to use the trimer 1rd8 to replace the trimer HAs
corresponding to 3 gbn, and the trimer 2 ibx to replace the
trimer corresponding to 3 gbm, respectively. We obtain a docked
pose for 1rd8-CR6261 and a docked pose for 2ibx-CR6261
through RosettaDock shown in Figure 4 (A)–(B).
Based on Figures 3 and 4, we conclude that RosettaDock offers
a real potential to capture the actual docked pose between a trimer
HA and an mAb. We are confident that the trimer HA-mAb
docked pose computed by RosettaDock is consistent with a global
free energy minimum.
To check whether or not CR62661 (F10) may dock with group
2 HAs, we only show that CR6261 (F10) may dock with the trimer
HA of H3 separated from 3 ztj. Similarly, to check whether or not
CR8020 may dock with group 1 HAs, we only show that CR8020
may dock with 1rd8. With the same operation, we obtain the
computed poses of CR6261 docked with H3 and F10 docked with
H3 as shown in Figure 5 (A)–(B), and the computed poses of
CR8020 docked with 1rd8 as shown in Figure 5 (C). Figure 5 (A)–
(C), shows that the footprints of CR6261 and F10 are both located
on the head of the spike of H3 HA and the footprint of CR8020 on
H3 HA is located in the middle of the stem.
Confirming that drugs bind to the cleft formed by HA and
mAb. Let CR6261&H3 denote the structure of Figure 5 (A),
F10&H3 denote the structure of Figure 5 (B), and CR8020&H1
denote the structure of Figure 5 (C). We prove that a drug may
bind to the fork formed by HA and mAb. However, an
unexpected result has occurred. All drugs are not sent to the fork
but to the trimer HA. We show the location of the pocket on
CR6261&H3, F10&H3 and CR8020&H1 explored by AutoDock
in Figure 6(A)–(C).
At first, we suspected this result was wrong because
CR6261&H3, F10&H3 and CR8020&H1 are computed struc-
tures. Nevertheless, we soon gave up this suspicion since we found
that the drug does not come to the fork but to the stem of HA
when we use the crystal structures 3 ztj and 3 fku (see Figure 7(A)–
(B)).
This indicates that pockets on CR6261&H3, F10&H3 and
CR8020&H1 explored by AutoDock are reasonable. Moreover,
we further find that these pockets on the complete 3 fku complex,
the complete 3 ztj complex, CR6261&H3, F10&H3 and
CR8020&H1 explored by AutoDock are quite different from the
pockets explored on the corresponding timer HAs. In fact, if we
only use 1rd8, 1 mql, 3 m5 g and 2 ibx as models, then the
pockets on each trimer HA are located almost in the same place
(see Figures S17–S20 in Section 1 of Information S1; these pockets
are very small and cannot be packed by Oselamivir or
Zananmivir). That is, the pocket explored by AutoDock on the
complete trimer HA-mAb complex is novel.
The above computational analysis tells us that a combined
protein may have many pockets but these pockets should be
explored using different subunits as the target proteins. In order to
show that clefts formed by CR6261 and H3 HA, F10 and H3 HA,
and CR8020 and H1 HA are pockets, we need to use a single
strain complex with CR6261, F10 and CR8020 as target proteins.
This is shown in Figure 7(A)–(C). Furthermore, we also find a
pocket for drugs on mAb if we only use mAb as the target protein.
The pockets of CR6261, CR8020, F10 and FI6 are shown in
Figures S14–S16 in Section 1 of Information S1.
Osletamivir may promote CR8020 to be a universal
mAb. We first note the structure of CR8020&H1, since the
footprint of CR8020 on H1 HA is at the stem and it covers the
epitope of HA. However, the number of non-covalent bonds
between HA and CR8020 is only 4. Furthermore, using
Table 6. The left and right contributors of Oseltamivir docked
with 3 gbn, 3 gbm, 3 fku, 3 ztn and 3 ztj for a pose with high
tolerance.
Target Left contributors on HA Right contributors on mAb
3 gbn 289N, 290S 70T, 72D, 79Y
3 gbm 289N, 290S, 291S 23K, 75A, 79Y
3 fku 35D, 38S, 40K, 293S 75S, 76T
3 sdy 18H, 20V, 17M, 18I, 20G, 56T
3 ztn 286I, A287N, 288T, 289S 28T, 29F, 30S, 31T, 73N, 74S, 76N
3 ztj 55P, 278I, 280E, 288I, 289P, 290N 28T, 29F, 30S, 76N
doi:10.1371/journal.pone.0037790.t006
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CR8020 ranges from 126 to136 kJ/mol (see Table 4). Therefore, a
drug may enhance CR8020 to become a universal mAb if and
only if it provides enough additional affinity so that CR8020 does
not unbind from H1 HA.
Based on the trinity symmetry of the HA-mAb complex, we
know that CR8020 in complex with H1 HA has at least nine
pockets, which are large enough to be bonded by Oseltamivir and
Zanamivir. In fact, three of them locate on the three faces of the
stem of trimer HA, three locate on the three forks and three on
three identical mAbs. Following from the CR8020&H1 case, we
find that Oseltamivir may help CR8020 to neutralize H1 influenza
viruses using the molecular mechanism described in Section 2.3. It
is important to note that the footprint of CR8020 on H1 HA is
located on the stem.
Following from the pose of Oseltamivir docked to the fork
formed by CR8020 and HA shown in Figure 8C, we use Ligand
Explorer to compute the distribution of non-covalent bonds. We
obtain a=10, b=9 and min {a, b}=9. Moreover, the associated
poses produced by shifting the center of the coordinates in the
optimal pose within 0.5A do not change the value of min{a, b}.
Thus, we lean towards the conclusion that Oseltamivir may
enhance CR8020 to become a universal mAb.
By comparison, the footprints of CR6261 and F10 on H3 HA
both are located on the head of the HA and therefore can at most
link to HA1 but cannot cause HA2 being separated from HA. In
other words, a drug may enhance CR6261 or F10 to neutralize
H3 influenza viruses if it prevents HA2 from dissociating from HA
and if it provides additional affinity so that CR6261 or F10 may
bind to the head of HA, too. Figure 6 (A)–(C) and Figure 8 (A)–(C)
show that the pocket on CR6261&H3 or F10&H3 is different from
the pocket on CR8020&H1. Therefore, the selection of drugs to
enhance CR6261 or F10 as a universal mAb is more difficult.
Moreover, based on a comparison of Figure 6A&Figure 8A with
Figure 6B&Figure 8B, we further find that pockets on
Figure 3. The validation of the reliability of RosettaDock. (A) The output of RosettaDock at the 338th iteration when the inputs are the trimer
HA and FI6 which are separated from 3 ztj. (B) The output of RosettaDock at the 263
rd iteration when the inputs are the trimer HA and F10 which are
separated from 3 fku.
doi:10.1371/journal.pone.0037790.g003
Figure 4. The validation of the reliability of RosettaDock. (A) The output of RosettaDock at the 200th iteration when the inputs are 1rd8 and
CR6261. (B) The output of RosettaDock at the 363
rd iteration when the inputs are 2 ibx and CR6261.
doi:10.1371/journal.pone.0037790.g004
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need to discuss CR6261 and F10 separately.
Azithromycin may promote CR6261 to become a
universal mAb. Figure 6(A) shows that that the footprint of
CR6261 on H3 HA is on the head. Then using Ligand Explorer,
we find only 11 non-covalent bonds between CR6261 and HA.
Furthermore, we use GROMACS to estimate the affinity between
CR6261 and HA which is found to be ranging from 98 to 111 kJ/
mol. In other words, the affinity between CR6261 and HA is really
weak. Moreover, the pocket of CR6261&H3 is very special. Two
pockets are degenerated into one pocket relative to 3 ztj.
Therefore, a drug that binds here must play two roles. One is to
keep HA1 and HA2 closer together and the other is to keep
CR6261 bound tightly to the head of H3 HA. It means that a drug
may be selected as a candidate if and only if it binds to HA1 (A-
chain), HA2 (B-chain) and CR6261 (L-chain) with a sufficient
number of non-covalent bonds. Based on the optimal poses of the
8 drugs binding to the pocket, we have the distribution of non-
covalent bonds as shown in Table 7.
Following from Table 7, we find that Azithcromycin is the best
candidate since the numbers of the non-covalent bonds between
Azithromycin and HA1 (HA2, CR6261) are 13, 16 and 10,
respectively. Moreover, the distribution of the non-covalent bonds
is not changed significantly if the pose is replaced by its associated
poses obtained by a slight shift since min{13, 16}=13 is about
260 kJ/mol. Consider the three identical faces of the trimer HA.
Then three molecules of Azithromcyin bind to the three identical
pockets, which adds 780 kJ/mol of binding affinity between HA1
and HA2. This is large enough to make sure that HA1 is tightly
linked to HA2. Moreover, the additional 10 non-covalent bonds
may also improve the affinity between CR6261 and HA.
Therefore, we believe that Azithcromycin is a good candidate to
enhance CR6261 to become a universal mAb.
How to promote F10 to become a universal mAb. The
footprint of F10 on H3 HA is also at the head. Moreover, the
number of the non- covalent bonds between F10 and HA is also 11
as computed by Ligand Explorer. Furthermore, the affinity
between F10 and HA estimated using GROMACS ranges from
170 to 180 kJ/mol (see Table 4). Figure 6B and 8B show that the
selection of drugs for F10 is neither the same as the selection for
CR6261 nor the selection for CR8020. In order to neutralize H3
influenza viruses, we should require the drug binding to the pocket
on the trimer HA such that HA does not be break. Then, a drug
molecule may bind to the exterior angle of the cleft formed by F10
and HA such that F10 does not unbind from HA. For this purpose
we should compute the numbers of non-covalent bonds and how
they are distributed in the corresponding pockets. We show these
values in Table 8.
Table 8 shows that a single drug cannot satisfy the requirement,
and therefore we recommend that two drugs together combine to
form a F10 –drug complex to enhance F10 to become a universal
mAb. The left part of Table 8 shows that Oseltamivir is a good
candidate to link the stem of the timer HA which does not become
broken since the numbers of non-covalent bonds between
Figure 5. The predicted structures output obtained by RosettaDock: (A) is the predicted structure of CR6261 docking with H3 HA which is
separated from 3 ztj, (B) is the predicted structure of F10 docked with H3 HA which is separated from 3 ztj, (C) is the predicted structure of CR8020
docked with 1rd8.
doi:10.1371/journal.pone.0037790.g005
Figure 6. The pockets explored by AutoDock based on the complete predicted structures: (A) is the pocket on the predicted structure
CR6261&H3, (B)is the pocket on the predicted structure F10&H3, (C) is the pocket on the predicted structure CR8020&H1.
doi:10.1371/journal.pone.0037790.g006
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(HA2), and between Oseltamivir and F-chain (HA2) are 21, 10
and 9, respectively. This strong affinity ensures that the B-, D- and
F-chains do not fall to pieces. The left part of Table 8 also shows
that Azichromycin does not bind to the pocket on the trimer HA
and therefore it does not compete with Oseltamivir to occupy this
pocket. The right part of Table 8 shows that Azithromycin has the
strongest ability to fill the exterior angle of the cleft formed by F10
and HA and may provide 15 non- covalent bonds to improve the
affinity between F10 and the stem of HA. Therefore, a possible
conclusion stemming from this analysis is to recommend that
Azithromycin and Oseltamivir are used together to promote F10
to neutralize H3 influenza viruses and so that F10 becomes a
universal mAb.
Results and Discussion
Summarizing the computational analysis in Sections 2.2 and
2.3, we have obtained the following results. We found a molecular
mechanism that explains why Oseltamivir and Zanamivir may
enhance the therapeutic efficacy of CR6261 for treating group 1
influenza viruses. Based on this mechanism, we further found that
Oseltamivir and Zanamivir may also enhance the therapeutic
efficacy of F10 or FI6 for treating group 1 influenza viruses and
the therapeutic efficacy of CR8020 or FI6 for treating group 2
influenza viruses. Moreover, these drugs may compensate for the
loss of affinity between HA and mAb due to some mutations of
amino acids within their footprints.
Using the RosettaDock software, we found that the footprint of
CR8020 on H1 HA is located in the middle of the stem of HA
which is better than the footprint of CR8020 on H3 HA.
However, the affinity between CR8020 and H1 HA is too low to
keep CR8020 and H1 HA together sufficiently tightly (see Table 4).
Therefore, we believe that a molecular mechanism to promote
CR8020 to become a universal mAb has been found. We only
need to identify a drug to enhance the affinity between CR8020
and the trimer HA so that CR8020 cannot unbind from HA.
Among the panel of 9 drugs examined, we found that Oseltamivir
squeezes through the selection process. It is possible that a better
drug can be found in the future using DrugBank or other chemical
databases.
Using the RosettaDock software, we found that the footprint of
CR8020 on H1 HA is located in the middle of the stem of HA
which is better than its footprint on H3 HA. However, the affinity
between CR8020 and H1 HA is too low to keep CR8020 and H1
HA bound sufficiently tightly together. Therefore, we believe we
have found a molecular mechanism required in the search for a
drug to enhance CR8020 to become a universal mAb.
Using the RosettaDock software, we found an explanation why
CR6261 (F10) does not neutralize group 2 influenza viruses,
namely we believe this is due to the fact that the footprints of
CR6261 and F10 are located at head of the HA. Therefore, a
molecular mechanism for using a drug to enhance CR6261 or F10
to become a universal mAb has been formulated. Based on the
mechanism and distribution of non-covalent bonds between a
Figure 7. The pockets explored by AutoDock based on the complete real structures: (A) is the pocket on 3 fku, (B)is the pocket on 3 tzj.
doi:10.1371/journal.pone.0037790.g007
Figure 8. The pockets on the predicted structures explored by AutoDock based on a subunit: (A)is the pocket explored based on one
subunit of the predicted structure CR6261&H3, (B)is the pocket explored based on one subunit of the predicted structure F10&H3, (C)is the pocket
explored based on one subunit of the predicted structure CR8020&H1.
doi:10.1371/journal.pone.0037790.g008
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candidate to enhance CR6261 to become an mAb. Moreover, we
recommend Azichromycin and Oseltamivir together as a candi-
date to enhance F10 to become a universal mAb.
We hope that using DrugBank and other medicinal chemistry
databases we will be able to find other drugs, which may play the
same role as Oseltamivir, Zanamivir or Azichromycin. However,
clinical experience shows that Azithromycin is safe (no reported
lethal side effects yet). Its half-life is long (about 18 hours) and
therefore it is convenient for clinical use. It causes no damage to
human proteins unless bacteria residing in the human body are
affected. Importantly, it is inexpensive. Hence, Azithromycin is a
good candidate to help CR6261 and F10 become universal
antibodies. Comparably, Oseltamivir has some side-effects and is
much more expensive without offering an advantage over
Azithromycin. Zanmivir is also a mature drug to treat influenza
viruses aiming at the target protein NA. However, its mode of
delivery is not convenient, although the price is not too high.
In summary, this study shows that Oseltamivir may improve the
therapeutic efficacy of FI6 to overcome drug resistance. As well,
Osetamivir may possibly enhance CR8020 to become a universal
mAb. Azithromycin may enhance CR6261 to become a universal
mAb and Azichromycin and Oseltamivir taken together may
enhance F10 to become a universal mAb. Therefore, we have
multiple choices to obtain cheap and safe antibody-based
therapies. We should carefully note the order of drug delivery.
The correct order should be that mAb docks with HA first, and
then a drug should be added. Otherwise, the function of the mAb
will be seriously lost. In fact, we have mentioned in Section 1 of
Information S1 that there is a large pocket on CR6261, FI6, and
CR8020. If we mix a drug and mAb first, then the drug will bind
to mAb and the activity of mAb will be reduced. In fact, an
experiment performed by a group at the Chinese CDC based on
Sichuan SWL1/2009(CNIC)and California/7/2009(CNIC) shows
that the therapeutic efficacy of the mixture of CR6261 and
Azithromycin to treat group 1 influenza viruses would be half of
the single CR6261.
Finally, we wish to comment on the use of MCABMSA
software. Over the last three years we have validated it on many
test datasets (general and specific) and compared it with MUSCLE
and MAFFT. Regarding computational speed, MCABMSA is
much fast than MUSCLE but almost the same as MAFFT. For the
size of the dataset, MCABMSA is much larger than MAFFT.
Regarding the SP-score, MCABMSA is superior to MUSCLE and
MAFFT on average. Based on the study presented in this paper,
MCABMSA emerges as having greater agility than the publicly
available multiple sequence alignment packages. Readers may
freely download it from http://mathbio.nankai.edu.cn/
aligneddatabase.
Finally, we would like to emphasize that AutoDock, Ligand
Explorer, GROMACS, and RosettaDock are four types of useful
software packages that perform computational drug design and
can reliably select antibody and drug complexes. We note that the
speeds of AutoDock, Dock and GROMACS are much lower. If
their speeds could be increased, they would be more useful in the
applications aimed at finding new targets for old drugs. For the
current cases studied here, we have to pay more attention to
choosing the panel of drugs in order for them to span a wider
spectrum of properties.
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